These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 9640815

  • 1. In-vitro activity of piperacillin and tazobactam combination against clinically significant bacteria.
    Obi CL, Makandiramba B, Robertson V, Tswana SA, Moyo SR, Nziramasanga P.
    East Afr Med J; 1998 Mar; 75(3):162-5. PubMed ID: 9640815
    [Abstract] [Full Text] [Related]

  • 2. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS, Tosin I, Sejas L, Miranda E.
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [Abstract] [Full Text] [Related]

  • 3. In-vitro disk diffusion sensitivity of meropenem against bacterial pathogens in Harare.
    Obi CL, Makandiramba B, Tswana SA, Robertson V, Moyo SR, Nziramasanga P.
    East Afr Med J; 1999 Jul; 76(7):365-9. PubMed ID: 10520362
    [Abstract] [Full Text] [Related]

  • 4. Aerobic bacteria isolated from blood cultures of patients and their antibiotic susceptibilities in Harare, Zimbabwe.
    Obi CL, Mazarura E.
    Cent Afr J Med; 1996 Dec; 42(12):332-6. PubMed ID: 9164012
    [Abstract] [Full Text] [Related]

  • 5. Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
    Stefani S, Bonfiglio G, Bianchi C, Zollo A, Nicoletti G.
    Drugs Exp Clin Res; 1998 Dec; 24(2):105-13. PubMed ID: 9675551
    [Abstract] [Full Text] [Related]

  • 6. A multicentre in vitro evaluation of piperacillin/tazobactam in Germany.
    Grimm H.
    Eur J Surg Suppl; 1994 Dec; (573):25-9. PubMed ID: 7524792
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF, Wildfeuer A.
    Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
    [Abstract] [Full Text] [Related]

  • 8. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
    Johnson DM, Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2002 May; 43(1):49-60. PubMed ID: 12052629
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients.
    Mokaddas E, Rotimi VO, Sanyal SC.
    J Chemother; 1998 Jun; 10(3):208-14. PubMed ID: 9669645
    [Abstract] [Full Text] [Related]

  • 10. Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
    Platsouka E, Zissis NP, Constantoulaki S, Paniara O.
    J Chemother; 1997 Oct; 9(5):336-40. PubMed ID: 9373788
    [Abstract] [Full Text] [Related]

  • 11. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group.
    Verbist L, Verhaegen J, Wouters C, Vandenhoven G.
    J Antimicrob Chemother; 1996 Feb; 37(2):285-93. PubMed ID: 8707738
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An evaluation of the in vitro activity of piperacillin/tazobactam.
    Daley D, Mulgrave L, Munro R, Neville S, Smith H, Dimech W.
    Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Scope of urinary pathogens isolated in the Public Health Bacteriology Laboratory, Harare: antibiotic susceptibility patterns of isolates and incidence of haemolytic bacteria.
    Obi CL, Tarupiwa A, Simango C.
    Cent Afr J Med; 1996 Aug; 42(8):244-9. PubMed ID: 8990570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.